Come dive into one of the curiously delightful conversations overheard at National Geographic’s headquarters, as we follow explorers, photographers, and scientists to the edges of our big, weird, beautiful world. Hosted by Peter Gwin and Amy Briggs.
…
continue reading
Content provided by PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Daniel S. Reich, MD, PhD - Targeting BTK: The Latest Data on the Evolving Treatment Landscape for Patients With MS
MP3•Episode home
Manage episode 364916447 series 9881
Content provided by PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Go online to PeerView.com/TFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this video, an expert reviews new data on the potential role of BTK inhibitors in the treatment of patients with multiple sclerosis presented at the American Academy of Neurology 2023 annual meeting. Learn how BTK inhibitors compare with anti-CD20 monoclonal antibodies and why this emerging class of DMTs may present a safe, effective, and highly selective treatment option with a low risk of opportunistic infections and possibly the ability to cross the blood–brain barrier, with results that may include a meaningful effect on proinflammatory cells in the CNS and the potential to prevent disability progression. Upon completion of this activity, participants should be better able to: Discuss the mechanism of action of Bruton tyrosine kinase (BTK) inhibitors in the targeted treatment of MS; Assess the current evidence regarding the efficacy, safety, and tolerability of BTK inhibitors for the treatment of MS; and Identify patients who may benefit from treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities
…
continue reading
89 episodes
Daniel S. Reich, MD, PhD - Targeting BTK: The Latest Data on the Evolving Treatment Landscape for Patients With MS
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
MP3•Episode home
Manage episode 364916447 series 9881
Content provided by PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Go online to PeerView.com/TFV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this video, an expert reviews new data on the potential role of BTK inhibitors in the treatment of patients with multiple sclerosis presented at the American Academy of Neurology 2023 annual meeting. Learn how BTK inhibitors compare with anti-CD20 monoclonal antibodies and why this emerging class of DMTs may present a safe, effective, and highly selective treatment option with a low risk of opportunistic infections and possibly the ability to cross the blood–brain barrier, with results that may include a meaningful effect on proinflammatory cells in the CNS and the potential to prevent disability progression. Upon completion of this activity, participants should be better able to: Discuss the mechanism of action of Bruton tyrosine kinase (BTK) inhibitors in the targeted treatment of MS; Assess the current evidence regarding the efficacy, safety, and tolerability of BTK inhibitors for the treatment of MS; and Identify patients who may benefit from treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities
…
continue reading
89 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.